Pfizer's Ibrance has been steamrolling since it nabbed an early FDA go-ahead last February. And even with competition coming up the pipeline from the company's Big Pharma rivals, Pfizer intends to keep it that way.
Research coming from the Fred Hutchinson Cancer Research Center and Johns Hopkins Medical Institute concludes that the deadly spreading of cancer occurs in clusters rather than single cancer cells.
Seno Medical hopes that its opto-acoustic breast cancer screener will be used to make it easier for physicians to identify benign masses than traditional ultrasound methods alone. In practice, this could help limit the need for biopsy to determine cancerous masses.
Backers of Israeli startup Vayyar Imaging do not have modest ambitions. They expect that the company's technology could revolutionize cancer detection and easily enable remote vital sign tracking--all that based on the company's 3-D imaging sensor technology that's touted as "making it possible to see through objects."
Novian Health is trumpeting promising results from a study of its innovative laser ablation treatment for breast cancer, putting wind in the company's sails as it eyes FDA approval for its device.
Roche has picked up another encouraging snapshot of promising early data for its PD-L1 checkpoint star atezolizumab--this time from a combination study involving triple negative breast cancer.
Most traditional chemotherapy is designed to kill errant cancer cells. But, unfortunately, sometimes it can also inadvertently damage healthy tissues as well. The FDA has cleared technology designed specifically to protect the hair follicles of female breast cancer patients as they undergo chemotherapy.
Researchers are starting a 9-month study of breast cancer patients using the Apple Watch to capture basic health data alongside treatment information and various aspects of patient health. The study uses an app that was developed by behavioral health tech company Polaris Health.
Puma Biotechnology said European regulators have opened a path to approval for its in-development breast cancer drug, clearing the way for a treatment that has divided analysts over the past few years.
Pfizer is enlisting the power of pictures for its next chapter in its metastatic breast cancer awareness campaign. For "Story Half Told," the pharma has hired 5 prominent Instagram photographers to chronicle the everyday lives of women living with MBC.